Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing Weekly

Hedge fund assets reach a record $2.13tln, but most are reducing risks – and other hedge fund news, Week 16

Saturday, April 21, 2012

In the week-ending 20 April, 2012, it was reported that former Goldman proprietary desk chief George Assaly would launch an equity-focused quant hedge fund named Alcova Asset Management; Zurich based global macro hedge fund manager Rialto Capital , announced plans to launch its second product during Q3; BlackRock launched its first U.S. equity hedge fund, the BlackRock Large Cap Series Hedge Fund; Julian Robertson’s Tiger Management said they would back a new hedge fund run by Knut Kjær; Miami-based Traders Alliance launched an in-house fund of hedge funds; and Renaissance Technologies begun trading its new hedge fund on March 1 with $3.5bn in assets.

Moore Capital Management-backed Salute Capital Management, run by Lev Mikheev announced plans to liquidate after its hedge fund lost 11% last year.

The Barclay Hedge Fund Index gained in March 0.19% (+5.69% YTD); The Dow Jones Credit Suisse Hedge Fund Index finished up +0.05% (+4.40% YTD); The Barclay CTA Index was down -1.21% (-0.27% YTD); The EDHEC Convertible Arbitrage Index went up +0.63% (+5.3% YTD); The Newedge CTA Index went down -1.88% (-0.45% YTD); The RBC Hedge 250 Index returned +0.36% (+3.35% YTD); The Hedge Fund Intelligence Global Composite Index was up +0.13% (+3.33% YTD); The Parker Global Strategies Currency Managers Index dropped -2.23% (+0.27%, YTD); The Scotiabank Canadian Hedge Fund Index ended March -4.06% (-3.77% YTD) on an asset weighted basis; And the HFRX Global Hedge Fund Index lost 0.33% MTD in April (+2.80% YTD).

Former Deutsche Bank Greg Lippmann’s credit hedge fund LibreMax Partners gained +1.41% in March (+5% YTD); BlackRock posted $572m in net income......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for